stockrow
Saturday 7 November 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- 0.00%
- Free cash flow
- −45.3%
- Total debt
- +558.3%
Quarter to September 2026, against a year earlier
0.19
0.00
0.00%
Follow IGC
Alert me
IGC Pharma, Inc. (IGC) P/E ratio
IGC Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | n/m |
| IGC IGC Pharma, Inc. | n/m |
| CVM Cel-Sci Corporation compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| CELU Celularity, Inc. compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| CRVO CervoMed Inc. compare | n/m |
| FLNA Cassava Sciences, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)